The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial

EuroIntervention 2018;14:1096-1103 published online May 2018. DOI: 10.4244/EIJ-D-17-01079

1. Contilia Heart and Vascular Center, Elisabeth Krankenhaus Essen, Essen, Germany; 2. Segeberger Kliniken GmbH, Herzzentrum, Bad Segeberg, Germany; 3. Pauls Stradin Clinical University Hospital, University of Latvia, Riga, Latvia; 4. Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; 5. Schwarzwald-Baar Klinikum Villingen-Schwenningen, Villingen-Schwenningen, Germany; 6. Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany; 7. Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany; 8. Klinikum Coburg GmbH, Coburg, Germany; 9. Universitätsklinikum Münster, Münster, Germany; 10. Department of Cardiology, Munich University Clinic, Ludwig-Maximilians University, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; 11. Städtisches Klinikum München GmbH, Klinikum Bogenhausen, Munich, Germany; 12. Universitätsklinikum Johannes Wesling, Minden, Germany; 13. Medizinisches Versorgungszentrum Prof. Mathey & Prof. Schofer, Hamburg, Germany; 14. Städtisches Klinikum München GmbH, Klinikum Schwabing München, Munich, Germany

Aims: Although several studies have shown positive outcomes after the use of drug-coated balloons (DCB) for in-stent restenosis (ISR), data on randomised controlled trials versus latest-generation drug-eluting stents (DES) are limited. Therefore, in this randomised trial, we sought to evaluate whether a butyryl-tri-hexyl citrate (BTHC)-based paclitaxel DCB is non-inferior to a biodegradable polymer sirolimus-eluting stent (BP-SES) therapy in patients with ISR in either a bare metal stent (BMS) or DES.

Methods and results: A total of 229 patients with ISR in BMS or DES from 13 German centres and one Latvian centre were 2:1 randomly allocated to DCB (n=157) or DES (n=72). The primary efficacy endpoint was defined as in-stent late lumen loss (LLL) at six months, and the primary safety endpoint was target lesion failure (TLF) at 12 months. LLL in the DCB arm was 0.03±0.40 mm compared to 0.20±0.70 mm in the DES arm (p=0.40). DCB proved to be non-inferior to DES (Δ = –0.17±0.52 mm, 97.5% CI –∞; –0.01]; p<0.0001). At 12 months, Kaplan-Meier TLF estimates were 16.7% in the DCB arm and 14.2% in the DES arm (p=0.65) and remained similar at 18 months (DCB versus DES: 17.4% versus 19.5%, p=0.88).

Conclusions: In patients with DES or BMS ISR, treatment with a paclitaxel DCB showed similar LLL at six months and TLF rates up to 18 months compared to a second-generation sirolimus DES.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial